On January 12, 2009, the FDA ruled that products containing pyridoxamine are excluded from the definition of dietary supplements as defined by the Invalid Link Removed.Invalid Link Removed The FDA stated that the status of Pyridorin as an investigational new drug, as a result of an application filed by BioStratum in July 1999 and effective on September 1, 1999, meant that "the marketing of pyridoxamine in a dietary supplement is essentially equivalent to the marketing of an investigational new drug as a dietary supplement" because there was an "absence of independent, verifiable evidence that the substance was marketed as a food or a dietary supplement prior to its authorization for investigation as a new drug."Invalid Link Removed
In 2006, Biostratum licensed its rights in Pyridorin to another company, NephroGenex Invalid Link Removed In 2008, NephroGenex restarted the clinical development of Pyridorin, which as of 2012 is still ongoing.